Stable bicarbonate ion-containing drug solution

ABSTRACT

The invention relates to a stable bicarbonate ion-containing drug solution, particularly a bicarbonate-containing drug solution for dialysis in which the stability has been improved by the presence of a phosphate ion. Further, the invention relates to a drug solution for acute blood purification, particularly a dialysate and a substitution liquid for acute blood purification to be mixed before use containing the drug solution. Still further, the invention relates to a dialysate and a substitution liquid for acute blood purification to be mixed before use in which the formation of insoluble fine particles or precipitates is prevented for a long time after mixing and with which hypokalemeia and hypophosphatemia are not caused.

This application is a Continuation of U.S. Ser. No. 12/680,857 filed May4, 2010, which is a National Stage Application of PCT/JP2008/068192,filed Oct. 6, 2008, which applications are incorporated herein byreference.

TECHNICAL FIELD

The present invention relates to a stable bicarbonate ion-containingdrug solution, particularly a bicarbonate-containing drug solution fordialysis, of which the stability is improved by the presence ofphosphate ion. Also, it relates to a drug solution for acute bloodpurification (i.e. blood purification in critical care), particularly adialysate or substitution liquid for acute blood purification of mixingtype on use, comprising said bicarbonate ion-containing drug solution.Further, it relates to a dialysate or substitution liquid for acuteblood purification of mixing type on use, which is prevented from theformation of insoluble fine particles or precipitates for a long timeafter mixing and does not cause hypokalemia and hypophosphatemia.

BACKGROUND ART

Homeostasis of a body fluid is significantly impaired by the rapidaccumulation of toxins or pathogens from diseases such as acute cardiacfailure, acute renal failure, acute hepatic failure, postoperativehepatic failure, sepsis, burn, toxicosis, fulminant hepatitis and acutepancreatitis. For treatment of the exacerbation of such acute or chronicdiseases, the acute blood purification therapy is applied thereto,because it is required to purify the blood and/or body fluid urgently soas to maintain the homeostasis and ameliorate the pathologicalcondition.

The acute blood purification therapy is a blood purification methodexperientially developed mainly in the critical care/intensive carefield, which removes unnecessary or toxic substances from bloods bydialysis, filtration, adsorption or separation (Non-Patent Reference 1).

A specific method for the acute blood purification therapy comprisesblood purification by an extracorporeal circulation of blood such ascontinuous hemodialysis (CHD), continuous hemofiltration (CHF),continuous hemodiafiltration (CHDF), hemodialysis (HD), hemoadsorption(HA), plasma adsorption (PA), plasma exchange (PE) or leukocytapheresis(LC). In these days, CHDF and PE are predominant due to the expansion oftheir application, the progress of the pathology resolution, etc.(Non-Patent Reference 2).

In the acute blood purification therapy, the use of a huge volume ofdialysate or substitute liquid is required for removal of detrimentalsubstances by utilization of the principle of diffusion,ultrafiltration, microfiltration, adsorption or the like.

The essential requirements for the dialysate or substitute liquid to beused in the acute blood purification therapy are as follows: (1)unnecessary or surplus substances are reduced; (2) essential orinsufficient substances are supplemented; (3) detrimental substances areundetectable or low enough to cause no problem; (4) essential substancesin a body are not reduced below normal concentrations; (5) metabolicsubstances taken up into a body are not so much as causing a burden tothe metabolic pathway; (6) osmotic pressure is close to that of blood;(7) stability is kept and handling is easy, etc. As the dialysate orsubstitution liquid presently used in the acute blood purificationtherapy, there are exemplified dialysates for artificial kidneys (e.g.Kindaly®Solution: Fuso Pharmaceutical Industries, Inc.) and substitutionliquids for filtration type artificial kidneys (e.g. Sublood®-B,Sublood®-BS: Fuso Pharmaceutical Industries, Inc.) which are sold in themarket for the therapy of chronic renal failure, because those meet saidrequirements and are easily available.

Many of these dialysates and substitution liquids contain sodiumbicarbonate. Therefore, the reaction of calcium and magnesium ions withbicarbonate ion therein proceeds with the lapse of time to forminsoluble fine particles or precipitates of carbonates. In order toavoid this problem, those are supplied as a kit formulation comprising asolution containing calcium ion (Ca²⁺) and magnesium ion (Mg²⁺)(hereinafter referred to as “Solution B”) and a solution containingbicarbonate ion (HCO₃ ⁻) (hereinafter referred to as “Solution A”, whichare kept separately and mixed together on use (Patent Reference 1).

-   Patent Reference 1: JP-A-2005-28108;-   Non-Patent Reference 1: Critical care/intensive care, Vol. 18, No.    1.2:3-4, 2006 (Japanese Journal);-   Non-Patent Reference 2: Japanese Journal of Clinical Medicine, Vol.    62 (Supp.):397-402, 2004.

An example of the dialysate or substitution liquid commerciallyavailable comprises sodium ion (Na⁺), 132-143 mEq/L; potassium ion (K+),2.0-2.5 mEq/L; calcium ion (Ca²⁺), 2.5-3.5 mEq/L; magnesium ion (Mg²⁺),1.0-1.5 mEq/L; chloride ion (Cl⁻), 104-114.5 mEq/L; bicarbonate ion(HCO₃ ⁻), 0-35.0 mEq/L; acetate ion (CH₃COO⁻), 3.5-40 mEq/L; andglucose, 0-200 mg/dL.

For instance, said Sublood®-BS comprises a double chambered containerhaving an upper chamber and a lower chamber separated with a separationwall, the upper and lower chambers containing respectively the followingSolutions B and A:

Solution B comprising the following compounds in a volume of 1010 mL(pH, 3.8-3.9; osmotic pressure ratio, 0.9-1.0): sodium chloride (NaCl),7.88 g; calcium chloride (CaCl₂. 2H₂O), 519.8 mg; magnesium chloride(MgCl₂.6H₂O), 205.4 mg; sodium acetate (CH₃COONa), 82.8 mg; glucose(C₆H₁₂O₆), 2.02 g; and glacial acetic acid (CH₃COOH), 360.0 mg; and

Solution A comprising the following compounds in a volume of 1010 mL(pH, 7.9-8.5; osmotic pressure ratio, 0.9-1.0): sodium chloride (NaCl),4.460 g; potassium chloride (KCl), 0.30 g; and sodium bicarbonate((NaHCO₃), 5.940 g.

On the use, the separation wall is broken to communicate the upper andlower chambers and combine Solutions A and B together, and the resultantmixture is administered from the side of the lower chamber. The doublechambered container as above is used for keeping separately such activecomponents which are expected to be reacted in the coexistence of themas bicarbonate ion and calcium and/or magnesium ions.

Other examples of the drug solution comprising bicarbonate ion areperitoneal dialysate, bicarbonate Ringer's solution, high calorietransfusion, etc., and most of them also keep bicarbonate ion andcalcium and/or magnesium ions separately by accommodating them in adouble chambered container in order to avoid the reaction between them(cf. JP-A-11-197240, etc.).

DISCLOSURE OF INVENTION Problem to be Solved

However, conventional dialysates or substitution liquids as aboveproduce sometimes adverse effects in the acute blood purificationtherapy, because the electrolyte concentrations therein are adjusted tobe suitable for application not to patients in need of acute bloodpurification but to chronic renal failure patients.

For instance, the potassium ion concentration in commercially availabledialysates or substitution liquids is adjusted so low as 2.0-2.5 mEq/Lfor improvement of hyperkalemia. Therefore, the application of thosedialystates or substitution liquids to the case in need of acute bloodpurification having a serum potassium ion level of less than 4.0 mEq/Lbefore dialysis may produce removal of potassium ion and amelioration ofacidosis resulting in rapid depression of serum potassium ion level tocause a risk of induction of arrhythmia and digitalis intoxication.

Also, commercially available dialysates or substitution liquids areformulated for chronic renal failure patients requiring amelioration ofhyperphosphatemia and do not contain any phosphorous component. Becauseof this reason, their application to the case in need of acute bloodpurification having such a low phosphate ion level as 3.0 mg/dL or lessbefore dialysis may produce a risk of developing hypophosphatemia,leading to depression of immunity and, in a severe case,unconsciousness.

In the acute blood purification therapy using commercially availabledialysates or substitution liquids, it is thus needed to correct theelectrolyte concentrations by supplementing potassium and/or phosphateions through the blood circuit for prevention of hypokalemia orhypophosphatemia.

Further, an acetate was used as an alkalizing agent (i.e. blood buffer)for a dialysate in the past. Acetate ion is transferred through adialysis membrane into blood and then metabolized to become bicarbonateion. However, as the result of having a dialyzer made of larger area andhigher performance, the loaded amount of acetate often exceeds thetreatment capacity of a living body and causes the symptoms of acetateintolerance such as reduction in blood pressure, bad feeling, headacheand nausea (Earnest D L et al.: Trans. Am. Soc. Artif. Intern. Organs14:434-437, 1968). A bicarbonate is currently used as the alkalizingagent in place of an acetate, but a small amount of acetate is yetcontained for stabilization of pH. Therefore, a dialysate orsubstitution liquid free of acetate ion is needed for avoiding thesymptoms of acetate intolerance.

The problems as stated above may be considered to solve by makingconventional dialysates or substitution liquids higher in potassium ionconcentration, incorporated with phosphate ion and/or not using anycompound producing acetate ion. However, dialysates or substitutionliquids have a possibility of affording a delicate and significantinfluence on the physiological state or condition of a living body, andtherefore it is hardly predictable if a desired effect would be actuallyobtained by said modifications. In addition, as well known, phosphateion reacts with calcium and/or magnesium ions to form insoluble fineparticles or precipitates like bicarbonate ion. Therefore, it isunlikely that incorporation of phosphate ion into dialysates orsubstitution liquids would give a stable solution.

In addition, as stated above, it is difficult to keep bicarbonate ionand calcium and/or magnesium ions stable in a drug solution containingsodium bicarbonate for a long time. Because of this reason, a solutioncontaining bicarbonate ion and a solution containing calcium and/ormagnesium ions are prepared separately and mixed together just beforethe administration to a patient. However, after mixing, bicarbonate ionis released as carbon dioxide gas from the mixed solution with lapse oftime so that the pH value rises and, in case of it being over around7.5, the formation of insoluble fine particles or precipitates maystart. In the acute blood purification therapy, blood purification isperformed especially in the coexistence of bicarbonate ion and calciumand/or magnesium ions over a long period of time, and therefore theformation of insoluble fine particles or participates such as calciumand/or magnesium carbonates causes a big problem.

Recently, there has been developed a drug solution of single type, inwhich bicarbonate ion and calcium and/or magnesium ions coexist(Japanese Patent No. 3003504). In this drug solution, citric acid orcitrate ion is used as a pH adjuster, by which the pH is adjusted to pH7.0-7.8 to prevent the formation of insoluble fine particles orprecipitates and provide a stable electrolyte infusion.

As stated above, citric acid or citrate ion is used as a pH adjuster inthe formulation of infusion, but care must be taken for exertion of onlythe desired pH adjusting effect without any adverse effect such ascitrate intoxication or drop of calcium ion concentration caused by thechelating action of citrate ion. The symptoms of citrate intoxicationinclude reduction in blood pressure, depression of cardiac function,abnormality on electrocardiogram (ECG), etc., and it is reported thatthe cause of them is the lowering of calcium ion concentration in blooddue to citric acid (Modern Medical Laboratory, Vol. 19, No. 2, 1991).Especially in case of an infusion which is administered directly into ablood vessel, it is not rare that the dosage of the drug solution isover 1-2 L. Also, in the acute blood purification therapy, the volume ofa drug solution for substitution may sometimes reach to so large asseveral tens liters. With increase of the dosage, the amount of citrateto be administered to a patient becomes larger, whereby the occurrenceof citrate intoxication, the depression of blood calcium ionconcentration due to the chelating action of citrate ion, etc. may takeplace causing a problem for safety.

Means to Solve Problem

As a result of the extensive study, it has now have been found that adrug solution for acute blood purification of good stability, which doesnot induce the development of hypokalemia or hypophosphatemia, can beprovided by keeping the concentrations of potassium ion and phosphateion within certain ranges. It has also been found that a drug solutionfor acute blood purification of good stability, which does not inducethe symptoms of acetate intolerance, can be provided by avoiding the useof any acetate compound producing acetate ion in the drug solution. Thedrug solution as above comprises calcium and/or magnesium ions but theincorporation of phosphate ion therein does not give insoluble phosphatesalt. Further, said drug solution comprises bicarbonate ion and calciumand/or magnesium ions, but the presence of phosphate ion prevents theformation of insoluble carbonate salt even after a long period of timeaffording such a high pH value as 7.5 or more. These technical effectsare entirely of unexpected nature. The present invention is based on theabove findings.

Accordingly, the present invention provides a stable drug solution, inwhich the formation of insoluble fine particles or precipitates isprevented for a long time, characterized in that the drug solutioncomprises phosphate ion in the coexistence of bicarbonate ion andcalcium and/or magnesium ions. It also provides a stable drug solutionfor acute blood purification, in which the formation of insoluble fineparticles or precipitates is prevented for a long time, characterized inthat the drug solution contains potassium ion and phosphate ion, thepotassium ion concentration being higher than that in conventionaldialysates or substitution liquids. In the drug solution as above, it ispreferred to maintain the potassium ion concentration within a range of3.5-5.0 mEq/L and the phosphate ion concentration within a range of2.3-4.5 mg/dL. Maintenance of the potassium ion concentration within theabove range is for prevention of the development of hypokalemia.Maintenance of the phosphate ion concentration within the above range isfor prevention of the development of hypophosphatemia with keeping thestability of the drug solution. At least within the above range, ahigher phosphate ion concentration may retain the stability of the drugsolution for a long time. In addition, it is preferred for prevention ofthe development of acetate intolerance that the drug solution is free ofacetate ion.

Since the drug solution of the present invention comprises bicarbonateion and calcium and/or magnesium ions as the essential components, thereremains a possibility that insoluble fine particles or precipitates maybe formed by the reaction of these ions, despite the presence ofphosphate ion. Therefore, it is preferred to keep an aqueous solutioncomprising bicarbonate ion and an aqueous solution comprising calciumand/or magnesium ions in separate containers and combine those solutionson use to make a mixture of them. Usually, bicarbonate ion is containedin Solution A to be accommodated in a lower chamber of a doublechambered container, and calcium and/or magnesium ions are contained inSolution B to be accommodated in an upper chamber. Potassium ion andphosphate ion may be incorporated together or individually in either oneor both of Solutions A and B.

Effect of Invention

The dialysate or substitution liquid for acute blood purificationprovided by the present invention do not cause hypokalemia orhypophosphatemia, and it is not needed to revise the electrolyteconcentrations during the acute blood purification therapy. Also, incase of acetate ion being not contained, it may be used for patients ofacetate intolerance with safety. Further, the bicarbonate ion-containingdrug solution of mixing type on use provided by this invention isprevented from formation of insoluble fine particles or precipitatessuch as calcium carbonate or magnesium carbonate over a long time aftermixing and therefore suitable for the use in the acute bloodpurification therapy over a long period of time.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 shows a double chambered container of double bag type providedwith a separation wall which is breakable for communication between thechambers.

EXPLANATION OF NUMERAL SIGN

-   1: Double chambered container accommodating the drug solution of the    present invention;-   2: Separation wall breakable for communication;-   3: Lower chamber (Chamber A; administration side):-   3′: Upper chamber (Chamber B);-   4: Heat seal portion;-   5: Opening gate as a port for administration of the drug solution    provided with a stopper, for instance, made of rubber or the like;-   6: Opening as a port for supplying the drug solution.

BEST MODE FOR CARRYING OUT INVENTION

In an embodiment of the present invention, there is provided a drugsolution of mixing type on use, especially a dialysate or substitutionliquid for acute blood purification of mixing type on use, whichcomprises Solution B comprising a phosphorous component, preferablyphosphate ion or a phosphate. In a preferred embodiment, there isprovided a drug solution of mixing type on use, especially a dialysateor substitution liquid for acute blood purification of mixing type onuse, which comprises Solution A comprising at least sodium ion,bicarbonate ion and water and Solution B comprising at least sodium ion,chloride ion, phosphate ion and water.

In another embodiment of this invention, there is provided a drugsolution of mixing type on use, especially a dialysate or substitutionliquid of mixing type on use for acute blood purification, whichcomprises Solution A comprising sodium ion, potassium ion, chloride ion,bicarbonate ion and water and Solution B comprising sodium ion,potassium ion, calcium ion, magnesium ion, chloride ion, phosphate ion,glucose and water, those Solutions being combined together on use togive the drug solution.

In another embodiment of this invention, there is provided a drugsolution of mixing type on use, especially a dialysate or substitutionliquid of mixing type on use for acute blood purification, whichcomprises Solution A comprising sodium bicarbonate, potassium chloride,sodium chloride and water and Solution B comprising sodium chloride,potassium chloride, calcium chloride, magnesium chloride, sodiumdihydrogen phosphate, glucose and water, those Solutions being combinedtogether on use to give the drug solution.

In another embodiment of this invention, there is provided a drugsolution of mixing type on use, especially a dialysate or substitutionliquid of mixing type on use for acute blood purification, whichcomprises Solution A comprising sodium ion, potassium ion, chloride ion,bicarbonate ion, phosphate ion and water and Solution B comprisingsodium ion, potassium ion, calcium ion, magnesium ion, chloride ion,glucose and water, those solutions being combined together to give thedrug solution.

In another embodiment of this invention, there is provided a drugsolution of mixing type on use, especially a dialysate or substitutionliquid of mixing type on use for acute blood purification, whichcomprises Solution A comprising sodium bicarbonate, potassium chloride,sodium chloride, disodium hydrogen phosphate and water and Solution Bcomprising sodium chloride, potassium chloride, calcium chloride,magnesium chloride, glucose and water, those Solutions being combinedtogether on use to give the drug solution.

In another embodiment of this invention, there is provided a drugsolution of mixing type on use, especially a dialysate or substitutionliquid of mixing type on use for acute blood purification, whichcomprises Solution A comprising sodium bicarbonate, potassium chloride,sodium chloride and water and Solution B comprising sodium chloride,calcium chloride, magnesium chloride, glucose and water, at least one ofSolutions A and B comprising further a phosphate compound and thoseSolutions being combined together on use to give the drug solution.

In a further embodiment of the invention, there is provided a drugsolution of mixing type on use, especially a dialysate or substitutionliquid of mixing type on use for acute blood purification, which has thesame composition as that of any one of the above embodiments, a mixedsolution of Solutions A and B having a potassium ion concentrationwithin a range of 3.5-5.0 mEq/L.

In a further embodiment of the invention, there is provided a drugsolution of mixing type on use, especially a dialysate or substitutionliquid of mixing type on use for acute blood purification, which has thesame composition as that of any one of the above embodiments, a mixedsolution of Solutions A and B having a phosphate ion concentrationwithin a range of 2.3-4.5 mg/dL.

In a further embodiment of the invention, there is provided a drugsolution of mixing type on use, especially a dialysate or substitutionliquid of mixing type on use for acute blood purification, whichcomprises Solution A comprising sodium chloride (NaCl) (4.640 g),potassium chloride (KCl) (0.298 g), sodium bicarbonate (NaHCO₃) (5.377g) and water per 1000 mL and Solution B comprising sodium chloride(NaCl) (7.598 g), potassium chloride (KCl) (0.298 g), calcium chloride(CaCl₂.2H₂O) (0.368 g), magnesium chloride (MgCl₂. 6H₂O) (0.203 g),sodium dihydrogen phosphate (NaH₂PO₄.2H₂O) (0.403 g), glucose (C₆H₁₂O₆)(2.00 g) and water per 1000 mL, those Solutions being combined togetherto give the drug Isolution.

In a further embodiment of the invention, there is provided a drugsolution of mixing type on use, especially a dialysate or substitutionliquid of mixing type on use for acute blood purification, whichcomprises Solution A comprising sodium chloride (NaCl) (4.382 g),potassium chloride (KCl) (0.298 g), sodium bicarbonate (NaHCO₃) (5.377g), disodium hydrogen phosphate (Na₂HPO₄.12H₂O) (0.925 g) and water per1000 mL and Solution B comprising sodium chloride (NaCl) (7.706 g),potassium chloride (KCl) (0.298 g), calcium chloride (CaCl₂.2H₂O) (0.368g), magnesium chloride (MgCl₂.6H₂O) (0.203 g), glucose (C₆H₂O₆) (2.00 g)and water per 1000 mL, those Solutions being combined together on use togive the drug solution.

In a preferred embodiment of the invention, there is provided a drugsolution of mixing type on use, especially a dialysate or substitutionliquid of mixing type on use for acute blood purification, which iscapable of retaining the potassium ion concentration in plasma within anormal range without a significant variation of the inorganic phosphateion (iP) concentration in plasma over 24 hours from the beginning of theacute blood purification therapy when a mixed solution of Liquids A andB is administered to a mammal (including human).

In a further embodiment of the invention, there is provided a drugsolution of mixing type on use, especially a dialysate or substitutionliquid of mixing type on use for acute blood purification, which iscapable of not causing the development of acetate intolerance to amammal (including human) of acetate intolerance when a mixed solution ofSolutions A and B is administered to the mammal (including human).

In a preferred embodiment of the invention, there is provided acontainer accommodating a drug solution of mixing type on use,especially a dialysate or substitution liquid of mixing type on use foracute blood purification, which comprises an upper chamber and a lowerchamber divided with a separation wall and a closed opening gateprovided at the bottom of the lower chamber and accommodates Solution Acomprising sodium ion, potassium ion, chloride ion and bicarbonate ionin the lower chamber and Solution B comprising sodium ion, potassiumion, calcium ion, magnesium ion, chloride ion and glucose in the upperchamber, at least one of Liquids A and B comprising additionallyphosphate ion and the separation wall being broken on use to combineSolutions A and B together. Preferably, said separation wall is easilybreakable.

In a further embodiment of the invention, there is provided thecontainer as above, which is provided with a suspending means at the topof the upper chamber. An example of the suspending means is a hole forhanging.

In a still further embodiment of the invention, there is provided eitherone of the containers as above, wherein the separation wall is providedto make the capacities of the upper and lower chambers equal or nearlyequal.

In a still further embodiment of the invention, there is provided anyone of the containers as above, which is made of an elastic andtransparent plastic material.

In a still further embodiment of the invention, there is provided anyone of the containers as above, wherein Solution A is an aqueoussolution comprising sodium bicarbonate, potassium chloride and sodiumchloride and Solution B is an aqueous solution comprising sodiumchloride, potassium chloride, calcium chloride, magnesium chloride andglucose, at least one of Solutions A and B comprising further aphosphate compound.

The container according to the invention may comprise two or morechambers for accommodating a drug solution. For instance, it may be acontainer comprising an upper chamber (Chamber B) and a lower chamber(Chamber A; administration side) divided with a separation wall which isbreakable to communicate those chambers. The upper chamber is a chamberaccommodating a solution as one of the constituents of the drug solutionand being to be positioned at an upper side on administration of thedrug solution. For instance, it is indicated by the numeral 3′ inFIG. 1. The separation wall to be broken for communication may beconstructed in any optional state or form, for instance, as a wallformed by separable melt-adhesion seal, a wall formed by fastening witha clip or a wall formed with an easily breakable material. From theviewpoint of simplicity in construction, preferred is a container havinga separation wall formed as a weakly sealed portion by heat fusion tomake readily separable. The separation wall of such container is readilybroken by application of a pressure from the outside onto either one ofthe chambers so as to make the sealed portion separated, thereby thesolutions in the chambers being mixed together aseptically.

The sealing may be made weakly by fusing two opposite films to make thefusion separable with ease. Such fusion may be prepared by aconventional procedure for preparation of a double chambered containersuch as a double bag. For instance, an adhesive resin may be applied tothe surfaces of the films to be combined. Also, a fusible resin may besandwiched between the films, followed by heat fusion. Further, theheating temperature for sealing may be set at a temperature somewhatlower than a perfect fusion temperature.

In the accompanying drawing, FIG. 1 shows an example of a doublechambered container of double bag type provided with a separation wallwhich is easily breakable. In FIG. 1, the numeral 1 indicates a doublechambered container accommodating the drug solution of the invention,the numeral 2 indicates a separation wall which is easily breakable, thenumeral 3 indicates a lower chamber (Chamber A; administration side),the numeral 3′ indicates an upper chamber (Chamber B) and the numeral 4indicates a heat fused part.

The container 1 is provided with an opening gate 5 as an administrationport having a stopper made of rubber or the like on one edge and anopening 6 as a supply port on the other edge. In FIG. 1, the container 1is divided into two chambers, i.e. the upper chamber and the lowerchamber. However, the number of chambers is not limitative and also thecontainer may be divided optionally to have three or more chambers, ifdesired. Further, no limitation is present on the shapes of thecontainer and each chamber as well as the width and shape of the sealingportion for a separation wall. Two chambers are usually formed bydividing them with one sealing, but two or more sealing may be appliedto form three or more chambers.

The double chambered container for accommodating a drug solution ofmixing type on use according to the invention is usually prepared by theuse of film sheets made of any synthetic resin as conventionallyemployed for preparation of containers for accommodating medicinalinfusions. Examples of the film sheets are mono-layer films, laminatedfilms, etc. made of low density polyethylene, ultra-low densitypolyethylene, high density polyethylene, polypropylene, ethylene-vinylacetate copolymer, polyester, polyvinyl chloride, polybutadiene,polyimide, ethylene-methacrylate copolymer, ethylene-propyleneelastomer, etc. The film sheets may be prepared by a per se conventionalprocedure such as blow molding, inflation molding, T-die molding,multi-layer molding or co-extrusion molding.

A double chambered container accommodating different solutionsseparately in different chambers divided with a separation wall which isbreakable for communication can be prepared by a per se conventionalprocedure. Such conventional procedure will be briefly illustratedbelow.

A laminated film consisting of three layers, i.e. an inner layer of lowdensity polyethylene (0.1 mm thick), a middle layer ofethylene-propylene elastomer (0.3 mm thick) and an outer layer of highdensity polyethylene (0.1 mm thick) is prepared by co-extrusiontechnique. Two sheets of the laminated film are cut in a designed size,and an opening gate 5 as an administration port is inserted between thetwo sheets in a manner communicating with the chamber for accommodatinga drug solution. Then, the periphery 4 (except the portion correspondingto the opening 6 as a supply port) and the separation wall 2 aresubjected to heat fusion.

Into the double chambered container as prepared above, a drug solutionto be mixed on use may be filled in a per se conventional procedure. Forinstance, Solution A comprising sodium chloride (NaCl) (4.640 g),potassium chloride (KCl) (0.298 g) and sodium bicarbonate (NaHCO₃)(5.377 g) per 1000 mL is first filled in the chamber 3 through theopening gate 5, followed by closing said opening gate with a rubberstopper. Then, Solution B comprising sodium chloride (NaCl) (7.598 g),potassium chloride (KCl) (0.298 g), calcium chloride (CaCl₂.2H₂O) (0.368g), magnesium chloride (MgCl₂.6H₂O) (0.203 g), sodium dihydrogenphosphate (NaH₂PO₄.2H₂O) (0.403 g), glucose (C₆H₁₂O₆) (2.00 g) per 1000mL is filled in the chamber 3′ through the opening 6, followed bysealing said opening by heat fusion. Finally, the resultant containerfilled in by the drug solution, i.e. Solutions A and B, is sterilized bysteaming at 110° C. under pressure for 30 minutes according to theguidance of the Japanese Pharmacopoeia (JP) to obtain a final product.

Also, for instance, Solution A comprising sodium chloride (NaCl) (4.382g), potassium chloride (KCl) (0.298 g), sodium bicarbonate (NaHCO₃)(5.377 g) and disodium hydrogen phosphate (Na₂HPO₄.12H₂O) (0.925 g) per1000 mL is filled in the chamber 3 through the opening gate 5, followedby closing with a rubber stopper. Then, Solution B comprising sodiumchloride (NaCl) (7.706 g), potassium chloride (KCl) (0.298 g), calciumchloride (CaCl₂.2H₂O) (0.368 g), magnesium chloride (MgCl₂.6H₂O) 0.203 gand glucose (C₆H₁₂O₆) 2.00 g) per 1000 mL is filled in the chamber 3′through the opening 6, followed by heat fusion adhesion. Finally, theresultant container filled in by the drug solution, i.e. Solutions A andB, is sterilized by steaming at 100° C. under pressure for 30 minaccording to the guidance of JP to obtain a final product.

After accommodation of the drug solution in the double chamberedcontainer shown in FIG. 1 as above, heat sterilization is appliedthereto as exemplified above. The heat sterilization may be performed byautoclaved sterilization, hot water spray sterilization, hot watershower sterilization, hot water soaking sterilization or the like. Thesterilization condition may depend on the sterilization procedure asapplied and is generally heated at a temperature of 100-130° C.,preferably 105-120° C., for 15-30 minutes.

The thus obtained double chambered container in which the drug solutionis aseptically accommodated is preferably stored in an outer packagingcontainer made of a gas impermeable material in order to prevent thecontact with air. As the gas impermeable material suitable for thispurpose, there are known various kinds of materials such asethylene-vinyl alcohol copolymer, from which any one may be optionallychosen and used. Further, in order to keep the atmosphere in the outerpackaging container free of oxygen, the double chambered container maybe stored in the presence of a deoxidant and/or under an atmosphere ofnitrogen gas or carbon dioxide gas. Furthermore, an oxygen detector orthe like may be provided in the outer packaging container for thepurpose of detecting a pinhole.

In the present specification, the language “formation of insoluble fineparticles or precipitates is prevented for a long time” is intended tomean that the formation of insoluble fine particles or precipitates isprevented at least over 27 hours after the final drug solution such as amixed solution of Solutions A and B is prepared or inhibited even afterthe pH of the mixed solution rises to 7.5 or more.

The term “drug solution of mixing type on use” is intended to mean adrug solution consisting comprising Solutions A and B and being used(i.e. administered) after combination of those Solutions.

The term “drug solution for acute blood purification” means a dialysateor substitution liquid to be used in the acute blood purificationtherapy (i.e. the blood purification therapy in critical care). The term“acute blood purification therapy” is used in the same meaning ascommonly used in the related art field. The term “substitution liquid”is sometimes referred to as “rehydration”, “replacement fluid” or thelike. In addition, the term “drug solution of mixing type on use foracute blood purification” means a dialysate or substitution liquid to beused in the acute blood purification therapy, amongst drug solutions tobe mixed on use.

The term “Solution A” means a drug solution comprising at least sodiumion, bicarbonate ion and water. Preferably, it comprises sodium ion,potassium ion, chloride ion, bicarbonate ion and water.

The term “Solution B” means a drug solution comprising at least calciumion and/or magnesium ion and water. Preferably, it comprises sodium ion,calcium ion, magnesium ion, chloride ion, glucose and water. Still, thecomponents in Solutions A and B other than water may be formulated in asolid form and dissolved in water on use to make a solution form.

As stated above, the drug solution of the invention is characterized incomprising potassium ion and phosphate ion. The source of potassium ionmay be chosen from compounds capable of giving potassium ion in anaqueous solution such as inorganic potassium salts (e.g. potassiumchloride) and organic potassium salts (e.g. potassium lactate, potassiumgluconate). The source of phosphate ion may be chosen from compoundscapable of giving phosphate ion in an aqueous solution such asphosphoric acid, sodium phosphate, sodium dihydrogen phosphate anddisodium hydrogen phosphate. Further, compounds comprising potassium andphosphate ions such as potassium phosphate, dihydrogen potassiumphosphate and dipotassium hydrogen phosphate may be used as the sourceof potassium and phosphate ions.

The concentration of potassium ion in the drug solution is usually3.5-5.0 mEq/L, preferably 3.5-4.5 mEq/L, and the concentration ofphosphate ion is usually 2.3-4.5 mg/dL, preferably 2.5-4.0 mg/dL(especially 3.0 mg/dL or more). As stated above, the drug solution ofthe invention usually consists of two solutions, i.e. Solution A andSolution B, and the concentrations of potassium ion and/or phosphate ionin each of said two solutions may be so adjusted as giving theconcentrations as stated above in the drug solution obtained bycombination of said two Solutions.

Practical embodiments of the present invention will be hereinafterexplained more in details by way of Examples, but it is to be understoodthat those Examples are not intended to make any limitation onto thetechnical scope of the present invention. The apparatuses and reagentsused in those Examples are as follows:

-   -   Dialyzer (APS-08MD; membrane area, 0.7 m²; Lot No. 01Z182082;        Asahi Kasei Medical Co., Ltd.)    -   Blood circuit for sustained filtration (JCH-26S; Lot No. 012942;        UBE JUNKEN MEDICAL Co., LTD.)

Blood purification device (JUN-505; Serial No. UA034; UBE JUNKEN MEDICALCo., LTD.)

-   -   Solution sending pump (Masterflex L/S; Cole-Parmer)    -   Solution sending pump (Watson Marlow 505Di; Serial No.        B00005470, B00005471; WATSON-MARLOW)    -   Syringe pump (Terufusion Syringe pump STC-521; Serial No.        8063084; Termo)    -   Polygraph system (RM-7000; NIHON KOHDEN)        -   Amplifier for blood pressure measurement AP-641G        -   Blood pressure transducer (Lifekit; DX-312; Lot No. 107087)        -   Amplifier for bioelectricity AB-621G        -   Input box for bioelectricityJB-640G        -   Amplifier for copula AA-601H        -   Breath/pulse wave copula AR-650H        -   Temperature measurement unit AW-601H        -   Temperature copula AW-650H    -   Inhalation anesthesia apparatus    -   Universal blood gas analysis apparatus (i-STAT analyzer 300F;        Fuso Pharmaceutical Industries, Ltd.)    -   Universal blood gas analysis apparatus (i-STAT cartridge EG7+;        Lot No. M02164B; Fuso Pharmaceutical Industries, Ltd.)    -   Dry-type Clinical Chemistry Analyzer (FUJI DRI-CHEM 3030;        FUJIFILM Medical Co., Ltd.)    -   Dry-type Clinical Chemistry Analyzer (FUJI DRI-CHEM 800;        FUJIFILM Medical Co., Ltd.)    -   High speed micro centrifuge (MX-150; TOMY SEIKO CO., LTD.)    -   Substitution liquid for filtration type artificial kidneys        (Sublood-BS; Lot No. 02D11A; Fuso Pharmaceutical Industries,        Ltd.)    -   Lactate Ringer's solution (Lactate Ringer's solution “FUSO”;        Fuso Pharmaceutical Industries, Ltd.)    -   Isoflurane    -   Sodium taurocholate (Wako Pure Chemical Industries, Ltd.)    -   Benzylpenicillin potassium (PENICILLIN G POTASSIUM 500,000 UNITS        FOR INJECTION; Lot No. 7QC02P; MEIJI SEIKA KAISHA, LTD.)    -   Heparin sodium (Heparin sodium injection; Lot No. 02G08A; Fuso        Pharmaceutical Industries, Ltd.)

EXAMPLES Preparation of Acute Pancreatitis Model Animal

In a large animal facility of Fuso Pharmaceutical Industries, Ltd.(temperature, 23±5° C.; humidity, 50±20% RH; ventilation, 15-20times/hr; lighting, 12 hours (7:00-19:00)), 21 ma beagle dogs (eachweighing around 10 kg, Nosan Corporation) were accommodated each in astainless breeding case and bred with a solid feed (CREA Dog DietCD-5M™, CLEA Japan, Inc.) in an amount of about 300 g/day. Drinkingwater used was tap water, and the animals could be accessed ad libitumduring the test.

Under isoflurane inhalation anesthesia, the beagle dogs were each fixedin the back position, and then the common bile duct was exposed throughan abdominal incision and the incision was closed by a clamp. Theduodenum was incised, and a tube made of polyethylene (PE50, Becton,Dickinson and Company) was inserted from the minor duodenal papilla intothe accessory pancreatic duct. Then, 3% sodium taurocholatephysiological saline was injected retrogradely at 1.0 mL/kg/5 min toinduce acute pancreatitis.

During the preparation of the model and after the surgery, anappropriate infusion was administered in an appropriate amount.

After the surgery, a benzylpenicillin potassium injection (0.5 millionU/animal) was given intramuscularly once a day for two days to preventinfection, whereby acute pancreatitis model animals were prepared.

Example 1 (i) Preparation of Solution B, Followed by Filling in andSealing of Upper Chamber

The components in Table 1 are weighed, and glucose, sodium chloride,potassium chloride, magnesium chloride, calcium chloride and sodiumdihydrogen phosphate are added to and dissolved in water for injection(Japanese Pharmacopoeia (JP)), followed by filtration. To the filtrate,water for injection is added to make a designed volume. The thusobtained solution is subjected to sterilized filtration by the use of afine filter, and the filtrate is filled in the upper chamber of a doublebag made of colorless plastic (1000 mL/1000 mL). The opening, throughwhich the filtrate has been introduced, is fused by heating to seal. Thesolution prepared with the prescription of Table 1 and accommodated inthe upper chamber is called “upper chamber solution of Example 1”(Solution B).

TABLE 1 Amount Prescription (per 1000 mL) Upper chamber Sodium chloride(NaCl), JP 7.598 g solution of Potassium chloride (KCl), JP 0.298 gExample 1 Calcium chloride (CaCl₂•2H₂O), JP 0.368 g (Solution B)Magnesium chloride (MgCl₂•6H₂O) 0.203 g JSPI Sodium dihydrogen phosphate0.403 g (NaH₂PO₄•2H₂O) JSFA Glucose (C₆H₁₂O₆), JP 2.000 g Water forinjection, JP q.s.

(ii) Preparation of Solution A, Followed by Filing in and Sealing ofLower Chamber

The components in Table 2 are weighed, sodium chloride, potassiumchloride and sodium bicarbonate are added to and dissolved in water forinjection (JP), followed by filtration. To the filtrate, water forinjection is added to make a designed volume. The thus obtained solutionis subjected to sterilized filtration by the use of a fine filter, andthe filtrate is filled in the lower chamber of the double bag (1000mL/1000 mL) accommodating Solution B in the upper chamber as in (i). Theopening gate, through which Solution A has been introduced, is closedwith a rubber stopper, and the head of the rubber stopper is appliedwith a sealing cap, followed by fusion. The solution prepared with theprescription of Table 2 is called “lower chamber solution of Example 1”(Solution A).

TABLE 2 Amount Prescription (per 1000 mL) Lower chamber Sodium chloride(NaCl), JP 4.640 g solution of Potassium chloride (KCl), JP 0.298 gExample 1 Sodium bicarbonate 5.377 g (Solution A) (NaHCO₃), JP Water forinjection, JP q.s.

Example 2 (i) Preparation of Solution B, Followed by Filing in andSealing of Upper Chamber

The components in Table 3 are weighed, glucose, sodium chloride,magnesium chloride, and calcium chloride are added to and dissolved inwater for injection (JP), and hydrochloric acid is added thereto,followed by filtration. To the filtrate, water for injection is added tomake a designed volume. The thus obtained solution is subjected tosterilized filtration by the use of a fine filter, and the filtrate isfilled in the upper chamber of a double bag made of colorless plastic(1000 mL/1000 mL). The opening, through which the filtrate has beenintroduced, is fused by heating to seal. The solution prepared with theprescription of Table 3 and accommodated in the upper chamber is called“upper chamber solution of Example 2” (Solution B).

TABLE 3 Amount Prescription (per 1000 mL) Upper chamber Sodium chloride(NaCl), JP 7.706 g solution of Potassium chloride (KCl), JP 0.298 gExample 2 Calcium chloride (CaCl₂•2H₂O), JP 0.368 g (Solution B)Magnesium chloride (MgCl₂•6H₂O) 0.203 g JSPI Glucose (C₆H₁₂O₆), JP 2.000g Hydrochloric acid (HCl), JP q.s. Water for Injection, JP q.s.

(ii) Preparation of Solution A, Followed by Filing in and Sealing ofLower Chamber

The components in Table 4 are weighed, and sodium chloride, potassiumchloride, disodium hydrogen phosphate and sodium bicarbonate are addedto and dissolved in water for injection (JP), followed by filtration. Tothe filtrate, water for injection is added to make a designed volume.The thus obtained solution is subjected to sterilized filtration by theuse of a fine filter, and the filtrate is filled in the lower chamber ofthe double bag (1000 mL/1000 mL) accommodating Solution B in the upperchamber as in (i). The opening gate, through which Solution A has beenintroduced, is closed with a rubber stopper, and the head of the rubberstopper is applied with a sealing cap, followed by fusion. The solutionprepared with the prescription of Table 4 is called “lower chamberliquid of Example 2” (Solution A).

TABLE 4 Amount Prescription (per 1000 mL) Lower chamber Sodium chloride(NaCl), JP 4.382 g solution of Potassium chloride (KCl), JP 0.298 gExample 2 Sodium bicarbonate 5.377 g (Solution A) (NaHCO₃), JP Disodiumhydrogen phosphate 0.925 g (Na₂HPO₄•12H₂O) (JSFA) Water for injection,JP q.s.

Comparative Example (i) Preparation of Solution B, Followed by Fillingin and Sealing of Upper Chamber

The components in Table 5 are weighed, and sodium chloride, calciumchloride, magnesium chloride, sodium acetate, glucose and glacial aceticacid are added to and dissolved in water for injection (JP) followed byfiltration. To the filtrate, water for injection is added to make atotal volume of 1010 mL. The thus obtained solution is subjected tosterilized filtration by the use of a fine filter, and the filtrate isfilled in the upper chamber of a double bag made of colorless plastic(1000 mL/1000 mL). The opening, through which the filtrate has beenintroduced, is fused by heating to seal. The solution prepared with theprescription of Table 5 and accommodated in the upper chamber is called“upper chamber solution of Comparative Example” (Solution B). The upperchamber solution of Comparative Example has the same composition asSolution B of “Sublood®-BS” (Fuso Pharmaceutical Industries, Inc.).

TABLE 5 Amount Prescription (per 1000 mL) Upper chamber Sodium chloride(NaCl), JP  7.88 g solution of Calcium chloride (CaCl₂•2H₂O), JP 0.5198g Comparative Magnesium chloride (MgCl₂•6H₂O), 0.2054 g Example JSPI(Solution B) Sodium acetate (CH₃COONa), JSPI 0.0828 g Glucose (C₆H₁₂O₆),JP  2.02 g Glacial acetic acid, JP 0.3600 g Water for injection, JP q.s.

(ii) Preparation of Solution A, Followed by Filling in and Sealing ofLower Chamber

The components in Table 6 are weighed, and sodium chloride, potassiumchloride and sodium bicarbonate are added to and dissolved in water forinjection (JP), followed by filtration. To the filtrate, water forinjection is added to make a designed volume. The thus obtained solutionA is subjected to sterilized filtration by the use of a fine filter, andthe filtrate is filled in the lower chamber of the double bag (1000mL/1000 mL) accommodating Solution B in the upper chamber as in (i). Theopening gate, through which Solution A has been introduced, is closedwith a rubber stopper, and the head of the rubber stopper is appliedwith a sealing cap, followed by fusion. The solution prepared with theprescription of Table 6 is called “lower chamber solution of ComparativeExample” (Solution A). The lower chamber solution of Comparative Examplehas the same composition as Solution A of “Sublood®-BS”.

TABLE 6 Amount Prescription (per 1000 mL) Lower chamber Sodium chloride(NaCl), JP 4.460 g solution of Potassium chloride (KCl), JP 0.300 gComparative Sodium bicarbonate 5.940 g Example (NaHCO₃), JP (Solution A)Water for Injection, JP q.s.

<Qualitative Test>

The sugar and electrolyte concentrations (theoretical value) of a mixedsolution of the upper chamber solution of Example 1 (Solution B) and thelower chamber solution of Example 1 (Solution A), a mixed solution ofthe upper chamber solution of Example 2 (Solution B) and the lowerchamber solution of Example 2 (Solution A) and a mixed solution of theupper chamber solution of Comparative Example (Solution B) and the lowerchamber solution of Comparative Example (Solution A) are shown in Table7.

TABLE 7 Mixed Volume Na⁺ K⁺ Ca²⁺ Mg²⁺ Cl⁻ HCO₃ ⁻ glucose P CH3COO⁻solution (mL) mEq/L mEq/L mEq/L mEq/L mEq/L mEq/L mg/dL mg/dL mEq/L Ex.1 1000 138.0 4.0 2.5 1.0 112.2 32.0 100.0 4.0 — Ex. 2 1000 138.0 4.0 2.51.0 111.0 32.0 100.0 4.0 — Com. 1010 140.0 2.0 3.5 1.0 111.0 35.0 100.0— 3.5 Ex.

<CHDF Test> (Method 1)

Beagle dog acute pancreatitis models (3 animals) were weighed 2 daysafter the induction of pancreatitis, and inhalation anesthesia withisoflurane were applied to them. A cannula connected to a blood pressuretransducer was inserted into the right femoral artery and a rectaltemperature probe was inserted into the rectum for monitoring the bloodpressure and the body temperature, respectively. Measurement of theelectrocardiogram (ECG) was done in Lead II. An arteriovenous shunt(detachable at center) provided with a blood collecting port from theleft femoral artery to the right femoral vein was prepared. To inhibitclotting, an appropriate amount of heparin sodium injection (heparin)was administered from the blood collecting site of the arteriovenousshunt, and the injection was continued into a blood circuit thereafter.Five minutes after the administration of heparin, the blood access wasconnected with a blood circuit (JCH-26S, JUNKEN MEDICAL Co., LTD.) and adialyzer (APS-08MD, Asahi Kasei Medical CO., LTD.).

(Method 2)

After Method 1 above, CHDF was done over 24 hours under the followingconditions: blood flow rate, 20 mL/min; dialysate (Mixed solution ofExample 1) flow rate, 1200 mL/hr; substitution liquid (Mixed solution ofExample 1) flow rate, 300 mL/hr; filtrate (Mixed solution of Example 1)flow rate, 1500 mL/hr; and no water removal. 0, 3, 6, 9, 12, 15, 18, 21and 24 hours after the beginning of CHDF, heparinized blood (1.5 mL) wascollected from the blood collecting port (outlet venous blood). For thecollected heparinized blood, various instrumental analyses wereperformed.

In an analogous manner, CHDF was done using a mixed solution ofComparative Example as the dialysate and the substitution liquid, andvarious instrumental analyses were performed.

Test items: pH, PCO₂ (mmHg), PO₂ (mmHg), HCO₃ ⁻ (mmol/L), tCO₂ (mmol/L),sO₂ (%), BE (mmol/L), Hct (%), Hb (g/dL), Na⁺ (mEq/L), K⁺ (mEq/L), Cl⁻(mEq/L), Ca²⁺ (mEq/L), Mg²⁺ (mEq/L), Lac (mEq/L), Ca (mg/dL), Mg(mg/dL), iP (mg/dL), GPT (U/L), LDH (U/L), AMY (U/L), BUN (mg/dL), ALB(g/dL), GLU (mg/dL). The results are shown in Table 8 wherein an averageobtained from three beagle dogs is given.

TABLE 8 Before 1 Day 3% TAU Mixed abdominal after Time after beginningof CHDF (hr) CHDF solution incision surgeon 0 3 6 9 pH Com. 7.366 7.3837.437 7.422 7.446 7.452 Ex. Ex. 1 7.327 7.381 7.384 7.407 7.429 7.402PCO₂ Com. 34.9 36.9 27.4 34.6 33.7 32.9 (mmHg) Ex. Ex. 1 42.3 40.0 36.035.4 37.3 39.6 HCO₃ ⁻ Com. 20.0 22.1 18.7 22.8 23.4 23.2 (mmol/L) Ex.Ex. 1 22.3 24.0 21.7 22.5 24.9 24.9 tCO₂ Com. 21.1 23.2 19.5 23.8 24.424.2 (mmol/L) Ex. Ex. 1 23.6 25.2 22.8 23.5 26.0 26.1 Hct Com. 46 46 3433 31 31 (%) Ex. Ex. 1 49 48 36 32 29 28 Hb Com. 15.0 15.0 11.4 11.110.4 10.3 (g/dL) Ex. Ex. 1 16.1 15.4 11.9 10.5 9.7 9.6 Na+ Com. 149.7146.9 144.0 141.8 140.7 139.7 (mmol/L) Ex. Ex. 1 145.8 143.3 143.5 139.8138.3 137.3 K⁺ Com. 3.96 3.96 3.63 3.78 3.67 3.44 (mmol/L) Ex. Ex. 14.17 3.55 3.70 3.95 3.79 3.62 Cl⁻ Com. 115.2 110.6 114.4 109.9 109.4109.1 (mmol/L) Ex. Ex. 1 111.5 110.2 112.3 109.3 108.3 108.5 Ca2+ Com.1.15 1.16 1.20 1.21 1.21 1.17 (mmol/L) Ex. Ex. 1 1.24 1.23 1.24 1.161.14 1.14 Mg2+ Com. 0.35 0.46 0.45 0.42 0.42 0.41 (mmol/L) Ex. Ex. 10.44 0.47 0.46 0.43 0.42 0.40 Lac Com. 2.5 1.6 1.5 0.9 0.6 0.7 (mmol/L)Ex. Ex. 1 2.7 2.1 1.3 0.8 0.7 0.6 Ca Com. 9.8 9.7 9.1 9.2 9.0 8.7(mg/dL) Ex. Ex. 1 10.7 10.2 9.9 8.6 8.4 8.3 Mg Com. 1.5 1.7 1.5 1.5 1.51.5 (mg/dL) Ex. Ex. 1 1.7 1.8 1.7 1.7 1.6 1.5 IP Com. 3.8 3.6 3.8 5.14.7 4.4 (mg/dL) Ex. Ex. 1 5.0 3.9 5.4 5.9 5.4 5.3 AMYL Com. 885 71735698 3733 2955 2415 (U/L) Ex. Ex. 1 1175 10783 9591 4808 3793 3563 ALBCom. 3.1 3.3 2.5 2.4 2.2 2.1 (g/dL) Ex. Ex. 1 3.0 3.0 2.4 2.2 2.0 1.9GLU Com. 90 102 120 124 127 131 (mg/dL) Ex. Ex. 1 96 117 146 156 150 1453% TAU Mixed Time after beginning of CHDF (hr) CHDF solution 12 15 18 2124 pH Com. 7.446 7.431 7.431 7.437 7.428 Ex. Ex. 1 7.411 7.394 7.4067.419 7.422 PCO₂ Com. 33.6 35.3 34.1 32.4 34.6 (mmHg) Ex. Ex. 1 39.640.4 39.4 38.4 38.7 HCO₃ ⁻ Com. 23.4 23.7 22.8 22.0 23.0 (mmol/L) Ex.Ex. 1 25.4 24.9 24.9 25.1 25.4 tCO₂ Com. 24.4 24.8 23.9 23.0 24.1(mmol/L) Ex. Ex. 1 26.6 26.1 26.2 26.2 26.6 Hct Com. 30 30 30 30 29 (%)Ex. Ex. 1 24 28 27 26 26 Hb Com. 9.9 10.1 10.1 10.1 9.8 (g/dL) Ex. Ex. 18.0 9.3 8.8 8.6 8.7 Na+ Com. 140.2 139.2 138.1 138.3 137.8 (mmol/L) Ex.Ex. 1 136.7 136.7 136.6 134.9 135.0 K⁺ Com. 3.36 3.17 3.22 3.14 3.08(mmol/L) Ex. Ex. 1 3.63 3.65 3.58 3.54 3.43 Cl⁻ Com. 108.6 108.7 109.0108.6 108.7 (mmol/L) Ex. Ex. 1 108.4 107.8 107.9 107.7 107.5 Ca2+ Com.1.16 1.13 1.12 1.14 1.15 (mmol/L) Ex. Ex. 1 1.15 1.14 1.13 1.13 1.12Mg2+ Com. 0.40 0.38 0.38 0.38 0.39 (mmol/L) Ex. Ex. 1 0.40 0.39 0.390.39 0.38 Lac Com. 0.6 0.6 0.6 0.8 0.6 (mmol/L) Ex. Ex. 1 0.6 0.7 0.80.9 0.9 Ca Com. 8.4 8.3 8.2 8.1 8.0 (mg/dL) Ex. Ex. 1 8.3 8.3 8.3 8.28.1 Mg Com. 1.4 1.3 1.3 1.3 1.3 (mg/dL) Ex. Ex. 1 1.5 1.5 1.5 1.4 1.4 IPCom. 4.3 4.0 3.9 3.5 3.2 (mg/dL) Ex. Ex. 1 5.0 4.9 4.7 4.5 4.5 AMYL Com.2118 1942 1790 1717 1646 (U/L) Ex. Ex. 1 3159 2799 2415 2089 1847 ALBCom. 2.0 1.9 1.8 1.7 1.7 (g/dL) Ex. Ex. 1 1.8 1.8 1.7 1.6 1.5 GLU Com.130 129 130 133 126 (mg/dL) Ex. Ex. 1 142 141 140 142 137

(Results)

Reduction of potassium concentration after the beginning of CHDF withthe mixed solution of Example 1 was slower than that with the mixedsolution of Comparative Example, suggesting less induction ofhypokalemia. Also, reduction of inorganic phosphorus (iP) concentrationafter the beginning of CHDF with the mixed solution of Example 1 waslikewise slower than that with the mixed solution of ComparativeExample, suggesting less induction of hypophosphatemia. No significantdifference can be seen for other values measured. The above results thussuggest that the substitution liquid for acute blood purificationaccording to the present invention may sufficiently inhibit thedevelopment of hypokalemia and hypophosphatemia.

<Stability Test>

Measurement of the pH and properties (color and clearness) of a drugsolution for acute blood purification in the open system was done withvariation of the concentration of disodium hydrogen phosphate.

(1. Test Solutions)

1-1. Sodium chloride (77.0625 g), potassium chloride (2.9804 g), calciumchloride dihydrate (3.6827 g), magnesium chloride hexahydrate (2.0315g), glucose (20.0015 g) and 1 mol/L hydrochloric acid (2 mL) wereobtained, and water was added thereto to make a volume of 2 L (5 foldconc. Stock Solution B).

1-2. Sodium chloride (43.8236 g), potassium chloride (2.9797 g) andsodium bicarbonate (53.7711 g) were obtained, and water was addedthereto to make a volume of 2 L (5 fold conc. Stock Solution A).

1-3. Disodium hydrogen phosphate 12 hydrate (3.5804 g) was obtained, andwater was added thereto to make a volume of 100 mL (disodium hydrogenphosphate solution)

1-4. Disodium hydrogen phosphate 12 hydrate (0.1153 g) was obtained, and5 fold conc. Stock Solution A (100 mL) and water were added thereto tomake a volume of 500 mL, followed by bubbling with carbon dioxide gas tomake pH of about 7.5 (Solution A-1). Besides, water was added to 5 foldconc. Stock Solution B (100 mL) to make a volume of 500 mL (SolutionB-1). Solution A-1 (500 ml) and Solution B-1 (500 ml) were mixed gently(P 1 mg/dL), followed by bubbling with carbon dioxide gas to make pH ofabout 7.25.

1-5. Disodium hydrogen phosphate 12 hydrate (0.2312 g) was obtained, and5 fold conc. Stock Solution A (100 mL) and water were added thereto tomake a volume of 500 mL, followed by bubbling with carbon dioxide gas tomake pH of about 7.5 (Solution A-1). Besides, water was added to 5 foldconc. Stock Solution B (100 mL) to make a volume of 500 mL (SolutionB-1). Each 500 mL of Solution A-1 and Solution B-1 were mixed gently (P1 mg/dL), followed by bubbling with carbon dioxide gas to make pH ofabout 7.25.

1-6. Disodium hydrogen phosphate solution (0, 1, 2.5 or 5 mL) wasobtained, and 5 fold conc. Stock Solution A (100 mL) and water wereadded thereto to make a volume of 500 mL, followed by bubbling withcarbon dioxide gas to make pH of about 7.5 (Solutions A-2˜A-5). Besides,water was added 5 fold conc. Stock Solution B (100 mL) to make a volumeof 500 mL (Solution B-2). Solution A-2 (500 ml) and Solution B-2 (500ml) were mixed gently (P 1 mg/dL), followed by bubbling with carbondioxide gas to make pH of about 7.25. In an analogous manner, testsolutions were prepared with Solutions A-3-A-5. (The phosphate ionconcentrations are 0, 0.1, 0.25 or 0.5 mEq/L.)

(2. Date of Test)

Jul. 9 to 12, 2007 (phosphate ion: 1 mg/dL and 2 mg/dL)

Jul. 9 to 13, 2007 (phosphate ion: 0, 0.1, 0.25 and 0.5 mEq/L)

(3. Test Method)

3-1. Each test solution was poured gently into a 1 L volume plasticbottle, followed by gentle stirring with a rotary bob (9 mm).

3-2, pH and property (clearness) were measured.

(4. Test Results)

4-1. Phosphate ion: 1 mg/dL (0.32 mEq/L) and 2 mg/dL (0.65 mEq/L)

TABLE 9 1 mg/dL 2 mg/dL (0.32 mEq/L) (0.65 mEq/L) pH Precipitate pHPrecipitate Beginning 7.27 — 7.26 —  2 hrs 7.33 — 7.29 — 17 hrs 8.18 —8.07 — 18 hrs 8.23 — 8.12 — 20 hrs 8.29 — 8.19 — 24 hrs 8.41 — 8.32 — 42hrs 8.69 — 8.67 — 48 hrs 8.73 — 8.70 — 67 hrs 8.87 — 8.86 — 72 hrs 8.88— 8.89 —

4-2. Phosphate ion: 0, 0.1, 0.25 and 0.5 mEq/L

TABLE 10 0 mEq/L 0.1 mEq/L 0.25 mEq/L 0.5 mEq/L pH Precipitate pHPrecipitate pH Precipitate pH Precipitate Beginning 7.26 — 7.27 — 7.23 —7.27 —  2 hrs 7.48 — 7.44 — 7.45 — 7.45 —  4 hrs 7.60 — 7.52 — 7.53 —7.56 —  6 hrs 7.72 — 7.64 — 7.62 — 7.62 — 22 hrs 8.23 3+ 8.30 — 8.30 —8.28 — 24 hrs 8.30 3+ 8.36 — 8.38 — 8.35 — 27 hrs 8.40 3+ 8.42 — 8.42 —8.40 — 30 hrs 8.45 3+ 8.47 Flotage± 8.49 — 8.46 — 46 hrs 8.70 3+ 8.56 3+8.70 — 8.69 — 48 hrs 8.76 3+ 8.60 3+ 8.73 — 8.71 —

(5. Consideration)

From the results shown in Tables 9 and 10 above, it is understood thatthe formation of precipitates is significantly prevented byincorporation of phosphate ion into the drug solution. Even at such alow concentration as 0.1 mEq/L (0.31 mg/dL), it is recognized that theprecipitate formation is prevented to a certain extent.

In addition to the above, another comparative test was carried out usinga drug solution not containing phosphate ion and a drug solutioncontaining phosphate ion at 4 mg/dL. Nearly linear rise of the pH from7.23-7.29 to 7.89-7.94 was observed within 7 days, during which theparticle size and number of insoluble fine particles increasedsignificantly in the drug solution not containing phosphate ion but suchincrease was substantially not observed in the drug solution containingphosphate ion in spite of the pH rise as above.

INDUSTRIAL APPLICABILITY

According to the invention, there is provided a drug solution to bemixed on use which comprises sodium bicarbonate incorporated withphosphate ion. There is also provided a dialysate or substitution liquidfor acute blood purification, especially a dialysate or substitutionliquid for acute blood purification which does not cause hypokalemia andhypophosphatemia. There is further provided a dialysate or substitutionliquid to be mixed on use for acute blood purification which isprevented from production of insoluble fine particles or precipitatesover a long period of time after mixing.

1-31. (canceled)
 32. A stable bicarbonate ion-containing drug solutionof mixing type on use for acute blood purification, which comprises: asolution A comprising sodium ions, chloride ions, bicarbonate ions, andwater; and a solution B comprising sodium ions, calcium ions, magnesiumions, chloride ions, glucose, and water, wherein at least one of theSolution A and the Solution B comprises monophosphate ions, and neitherof the Solution A and the Solution B comprises acetate ions.
 33. Thedrug solution according to claim 32, wherein the Solution A comprisessodium ions, potassium ions, chloride ions, bicarbonate ions, and water,and the Solution B comprises sodium ions, potassium ions, calcium ions,magnesium ions, chloride ions, monophosphate ions, glucose, and water.34. The drug solution according to claim 33, wherein the Solution Acomprises sodium bicarbonate, potassium chloride, sodium chloride, andwater, and the Solution B comprises sodium chloride, potassium chloride,calcium chloride, magnesium chloride, sodium dihydrogen phosphate,glucose, and water.
 35. The drug solution according to claim 32, whereinthe Solution A comprises sodium ions, potassium ions, chloride ions,bicarbonate ions, monophosphate ions and water, and the Solution Bcomprises sodium ions, potassium ions, calcium ions, magnesium ions,chloride ions, glucose, and water.
 36. The drug solution according toclaim 35, wherein the Solution A comprises sodium bicarbonate, potassiumchloride, sodium chloride, disodium hydrogen phosphate, and water, andthe Solution B comprises sodium chloride, potassium chloride, calciumchloride, magnesium chloride, glucose, and water.
 37. The drug solutionaccording to claim 32, wherein a mixed solution of the Solution A andthe Solution B has a potassium ion concentration of 3.5 to 5.0 mEq/L.38. The drug solution according to claim 32, which retains a potassiumion concentration in plasma within a normal range without a significantvariation of the monophosphate ion concentration in plasma over 24 hoursfrom a beginning of an acute blood purification therapy when the mixedsolution of the Solution A and the Solution B is administered to amammal, which includes a human, as a dialysate or substitution liquid.39. The drug solution according to claim 32, which does not cause asymptom of acetate intolerance to a mammal, which includes a humanhaving acetate intolerance when the mixed solution of the Solution A andthe Solution B is administered to the mammal as a dialysate orsubstitution liquid.
 40. A container accommodating a drug solution ofmixing type on use for acute blood filtration, which comprises an upperchamber and a lower chamber divided with a separation wall and having aclosed opening gate provided at the bottom of the lower chamber, whereinthe lower chamber accommodates a Solution A comprising sodium ions,potassium ions, chloride ions, bicarbonate ions, and water, the upperchamber accommodates a Solution B comprising sodium ions, potassiumions, calcium ions, magnesium ions, chloride ions, glucose, and water,at least one of the Solution A and the Solution B further comprisesmonophosphate ions, and neither of Solutions A and B comprises acetateions, and the separation wall is broken upon use so as to combine theSolution A and the Solution B together.
 41. The container according toclaim 40, which further comprises a suspender at a top of the upperchamber.
 42. The container according to claim 40, wherein the separationwall divides the upper chamber and the lower chamber so that capacitiesof the upper chamber and the lower chamber are equal or nearly equal.43. The container according to claim 40, wherein the container is madeof an elastic and transparent plastic material.
 44. The containeraccording to claim 40, wherein the Solution A is an aqueous solutioncomprising sodium bicarbonate, potassium chloride, and sodium chloride,and the Solution B is an aqueous solution comprising sodium chloride,potassium chloride, calcium chloride, magnesium chloride, and glucose,and at least one of the Solution A and the Solution B further comprisesmonophosphate ions.
 45. A stable drug solution for acute bloodpurification comprising sodium ions, potassium ions, chloride ions,bicarbonate ions, calcium ions, magnesium ions, and glucose, butcomprising no acetate ions, wherein the stable drug solution furthercomprises monophosphate ions, by which production of insoluble fineparticles or precipitates in the sable drug solution is prevented for along time.
 46. The drug solution according to claim 45, in whichbicarbonate ions are held separately from the calcium ions and themagnesium ions until mixed together upon use of the drug solution,wherein production of insoluble fine particles or precipitates in thedrug solution is prevented for a long time.
 47. The drug solutionaccording to claim 45, which does not cause hypokalemia orhypophosphatemia.
 48. The drug solution according to claim 45, which istolerated by a patient having acetate intolerance.
 49. The drug solutionaccording to claim 46, which comprises the potassium ions in an amountto have a potassium ion concentration within a range from 3.5 to 5.0mEq/dL after mixing.
 50. The drug solution according to claim 47, whichcomprises: a Solutions A comprising sodium ions, potassium ions,chloride ions, bicarbonate ions, and water; and a Solution B comprisingsodium ions, potassium ions, calcium ions, magnesium ions, chlorideions, monophosphate ions, glucose, and water.
 51. The drug solutionaccording to claim 47, which comprises: a Solution A comprising sodiumions, potassium ions, chloride ions, bicarbonate ions, monophosphateions, and water; and a Solution B comprising sodium ions, potassiumions, calcium ions, magnesium ions, chloride ions, glucose, and water.52. The drug solution according to claim 45, which retains a potassiumion concentration in plasma within a normal range without a significantvariation of the monophosphate ion concentration in plasma over 24 hoursfrom a beginning of an acute blood purification therapy when a mixedsolution of the Solution A and the Solution B is administered to amammal, which includes a human, as a dialysate or substitution liquid.53. The drug solution of mixing type according to claim 32, wherein theSolution A and the Solution B are mixed upon use of the drug solution.54. The stable drug solution according to claim 45, wherein the stabledrug solution includes all the ions and the glucose upon use of thestable drug solution.
 55. The drug solution of mixing type according toclaim 32, wherein the mixed solution has the monophosphate ionconcentration in a range from 2.3 to 4.5 mg/dL, wherein themonophosphate ion concentration is calculated in terms of an inorganicphosphorus concentration.
 56. The container accommodating a drugsolution according to claim 40, wherein the mixed solution has themonophosphate ion concentration in a range from 2.3 to 4.5 mg/dL,wherein the monophosphate ion concentration is calculated in terms of aninorganic phosphorus concentration.
 57. The drug solution of mixing typeaccording to claim 45, wherein the mixed solution has the monophosphateion concentration in a range from 2.3 to 4.5 mg/dL, wherein themonophosphate ion concentration is calculated in terms of an inorganicphosphorus concentration.